Medtide Inc. (Stock Code: 03380.HK) is a peptide-focused contract research, development, and manufacturing organization (CRDMO), offering full-cycle services ranging from early-stage discovery, pre-clinical research and clinical development to commercial-stage production. The company is headquartered in Hangzhou, China and has commercial production bases and offices in both China and the United States.

Since establishment, Medtide Inc. has provided integrated synthesis, research, and manufacturing services to over 1,000 customers in the pharmaceutical and life sciences industries worldwide, covering projects in more than 50 countries. The company is dedicated to improving patients' lives and advancing the development of human health by maintaining a patient-centered approach.